Structural insights into the Middle East respiratory syndrome coronavirus 4a protein and its dsRNA binding mechanism

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Batool, Maria ^a   Shah, Masaud ^a   Patra, Mahesh Chandra ^a   Yesudhas, Dhanusha ^a   Choi, Sangdun ^a  

^a Ajou University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

DOUBLE STRANDED RNA; PROTEIN BINDING; VIRAL PROTEIN; VIRUS RNA;

AMINO ACID SEQUENCE; CONFORMATION; CORONAVIRUS INFECTION; GENETICS; HYDROGEN BOND; METABOLISM; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MOLECULAR MODEL; MUTAGENESIS; PHYSIOLOGY; STRUCTURE ACTIVITY RELATION; VIROLOGY;

AMINO ACID SEQUENCE; CORONAVIRUS INFECTIONS; HYDROGEN BONDING; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MUTAGENESIS; PROTEIN BINDING; RNA, DOUBLE-STRANDED; RNA, VIRAL; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL PROTEINS;

EID: 85029368956     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-11736-6     Document Type: Article

References (73)

1. Iwasaki, A. & Medzhitov, R. Control of adaptive immunity by the innate immune system. Nat Immunol 16, 343-353 (2015).
2. Akira, S., Uematsu, S. & Takeuchi, O. Pathogen recognition and innate immunity. Cell 124, 783-801 (2006).
3. Finlay, B. B. & McFadden, G. Anti-immunology: evasion of the host immune system by bacterial and viral pathogens. Cell 124, 767-782 (2006).
4. Zinzula, L. & Tramontano, E. Strategies of highly pathogenic RNA viruses to block dsRNA detection by RIG-I-like receptors: hide, mask, hit. Antiviral Res 100, 615-635 (2013).
5. Marc, D. Influenza virus non-structural protein NS1: interferon antagonism and beyond. J Gen Virol 95, 2594-2611 (2014).
6. Rodriguez-Madoz, J. R. et al. Inhibition of the type I interferon response in human dendritic cells by dengue virus infection requires a catalytically active NS2B3 complex. J Virol 84, 9760-9774 (2010).
7. Kindler, E. et al. Efficient replication of the novel human betacoronavirus EMC on primary human epithelium highlights its zoonotic potential. MBio 4, e00611-00612 (2013).
8. Zielecki, F. et al. Human cell tropism and innate immune system interactions of human respiratory coronavirus EMC compared to those of severe acute respiratory syndrome coronavirus. J Virol 87, 5300-5304 (2013).
9. Muller, M. A. et al. Human coronavirus EMC does not require the SARS-coronavirus receptor and maintains broad replicative capability in mammalian cell lines. MBio 3 (2012).
10. Chan, R. W. et al. Tropism of and innate immune responses to the novel human betacoronavirus lineage C virus in human ex vivo respiratory organ cultures. J Virol 87, 6604-6614 (2013).
11. Perlman, S. & Dandekar, A. A. Immunopathogenesis of coronavirus infections: implications for SARS. Nat Rev Immunol 5, 917-927 (2005).
12. Shalhoub, S., AlZahrani, A., Simhairi, R. & Mushtaq, A. Successful recovery of MERS CoV pneumonia in a patient with acquired immunodeficiency syndrome: a case report. J Clin Virol 62, 69-71 (2015).
13. Coleman, C. M. & Frieman, M. B. Emergence of the Middle East respiratory syndrome coronavirus. PLoS Pathog 9, e1003595 (2013).
14. Matthews, K. L., Coleman, C. M., van der Meer, Y., Snijder, E. J. & Frieman, M. B. The ORF4b-encoded accessory proteins of Middle East respiratory syndrome coronavirus and two related bat coronaviruses localize to the nucleus and inhibit innate immune signalling. J Gen Virol 95, 874-882 (2014).
15. van Boheemen, S. et al. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio 3 (2012).
16. Durai, P., Batool, M., Shah, M. & Choi, S. Middle East respiratory syndrome coronavirus: transmission, virology and therapeutic targeting to aid in outbreak control. Exp Mol Med 47, e181 (2015).
17. Raj, V. S. et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495, 251-254 (2013).
18. Josset, L. et al. Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus. MBio 4, e00165-00113 (2013).
19. Yang, Y. et al. The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists. Protein Cell 4, 951-961 (2013).
20. Goubau, D., Deddouche, S. & Reis e Sousa, C. Cytosolic sensing of viruses. Immunity 38, 855-869 (2013).
21. Li, J., Liu, Y. & Zhang, X. Murine coronavirus induces type I interferon in oligodendrocytes through recognition by RIG-I and MDA5. J Virol 84, 6472-6482 (2010).
22. Siu, K. L. et al. Middle east respiratory syndrome coronavirus 4a protein is a double-stranded RNA-binding protein that suppresses PACT-induced activation of RIG-I and MDA5 in the innate antiviral response. J Virol 88, 4866-4876 (2014).
23. Niemeyer, D. et al. Middle East respiratory syndrome coronavirus accessory protein 4a is a type I interferon antagonist. J Virol 87, 12489-12495 (2013).
24. Excler, J. L. et al. Toward Developing a Preventive MERS-CoV Vaccine-Report from a Workshop Organized by the Saudi Arabia Ministry of Health and the International Vaccine Institute, Riyadh, Saudi Arabia, November 14-15, 2015. Emerg Infect Dis 22 (2016).
25. Du, L., Tai, W., Zhou, Y. & Jiang, S. Vaccines for the prevention against the threat of MERS-CoV. Expert Rev Vaccines 15, 1123-1134 (2016).
26. Tai, W. et al. A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection. Virology 499, 375-382 (2016).
27. Jiaming, L. et al. The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection. Vaccine 35, 10-18 (2017).
28. Du, L. et al. Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines. Nat Commun 7, 13473 (2016).
29. Alharbi, N. K. Vaccines against Middle East respiratory syndrome coronavirus for humans and camels. Rev Med Virol (2016).
30. Sheahan, T. P. et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 9 (2017).
31. de Wilde, A. H. et al. Alisporivir inhibits MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus infection in a mouse model. Virus Res 228, 7-13 (2017).
32. Abuhammad, A., Al-Aqtash, R. A., Anson, B. J., Mesecar, A. D. & Taha, M. O. Computational modeling of the bat HKU4 coronavirus 3CLpro inhibitors as a tool for the development of antivirals against the emerging Middle East respiratory syndrome (MERS) coronavirus. J Mol Recognit (2017).
33. Kumar, V. et al. Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CLPro inhibitors. Antiviral Res 141, 101-106 (2017).
34. Gan, J. et al. Intermediate states of ribonuclease III in complex with double-stranded RNA. Structure 13, 1435-1442 (2005).
35. Masliah, G., Barraud, P. & Allain, F. H. RNA recognition by double-stranded RNA binding domains: a matter of shape and sequence. Cell Mol Life Sci 70, 1875-1895 (2013).
36. Zhang, Y. & Skolnick, J. TM-align: a protein structure alignment algorithm based on the TM-score. Nucleic Acids Res 33, 2302-2309 (2005).
37. Yang, J., Roy, A. & Zhang, Y. Protein-ligand binding site recognition using complementary binding-specific substructure comparison and sequence profile alignment. Bioinformatics 29, 2588-2595 (2013).
38. Gao, Y., Wang, R. & Lai, L. Structure-based method for analyzing protein-protein interfaces. J Mol Model 10, 44-54 (2004).
39. Stefl, R. et al. The solution structure of the ADAR2 dsRBM-RNA complex reveals a sequence-specific readout of the minor groove. Cell 143, 225-237 (2010).
40. Schaffer, A. A. et al. Improving the accuracy of PSI-BLAST protein database searches with composition-based statistics and other refinements. Nucleic Acids Res 29, 2994-3005 (2001).
41. Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. Basic local alignment search tool. J Mol Biol 215, 403-410 (1990).
42. Webb, B. & Sali, A. Comparative Protein Structure Modeling Using MODELLER. Curr Protoc Bioinformatics 47, 5 6 1-32 (2014).
43. Batool, M., Khalid, M. H., Hassan, M. N. & Fauzia Yusuf, H. Homology modeling of an antifungal metabolite plipastatin synthase from the Bacillus subtilis 168. Bioinformation 7, 384-387 (2011).
44. Roy, A., Kucukural, A. & Zhang, Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc 5, 725-738 (2010).
45. Kelley, L. A. & Sternberg, M. J. Protein structure prediction on the Web: a case study using the Phyre server. Nat Protoc 4, 363-371 (2009).
46. Schwede, T., Kopp, J., Guex, N. & Peitsch, M. C. SWISS-MODEL: An automated protein homology-modeling server. Nucleic Acids Res 31, 3381-3385 (2003).
47. Nielsen, M., Lundegaard, C., Lund, O. & Petersen, T. N. CPHmodels-3.0-remote homology modeling using structure-guided sequence profiles. Nucleic Acids Res 38, W576-581 (2010).
48. Hollingsworth, S. A. & Karplus, P. A. A fresh look at the Ramachandran plot and the occurrence of standard structures in proteins. Biomol Concepts 1, 271-283 (2010).
49. Benkert, P., Kunzli, M. & Schwede, T. QMEAN server for protein model quality estimation. Nucleic Acids Res 37, W510-514 (2009).
50. Wiederstein, M. & Sippl, M. J. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res 35, W407-410 (2007).
51. Pettersen, E. F. et al. UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem 25, 1605-1612 (2004).
52. Bhattacharya, A., Tejero, R. & Montelione, G. T. Evaluating protein structures determined by structural genomics consortia. Proteins 66, 778-795 (2007).
53. Berjanskii, M. et al. PROSESS: a protein structure evaluation suite and server. Nucleic Acids Res 38, W633-640 (2010).
54. Liu, L. et al. Structural basis of toll-like receptor 3 signaling with double-stranded RNA. Science 320, 379-381 (2008).
55. Macindoe, G., Mavridis, L., Venkatraman, V., Devignes, M. D. & Ritchie, D. W. HexServer: an FFT-based protein docking server powered by graphics processors. Nucleic Acids Res 38, W445-449 (2010).
56. Shah, M., Anwar, M. A., Park, S., Jafri, S. S. & Choi, S. In silico mechanistic analysis of IRF3 inactivation and high-risk HPV E6 species-dependent drug response. Sci Rep 5, 13446 (2015).
57. Capriotti, E., Fariselli, P. & Casadio, R. I-Mutant2.0: predicting stability changes upon mutation from the protein sequence or structure. Nucleic Acids Res 33, W306-310 (2005).
58. Kutzner, C. et al. Best bang for your buck: GPU nodes for GROMACS biomolecular simulations. J Comput Chem 36, 1990-2008 (2015).
59. Lindorff-Larsen, K. et al. Improved side-chain torsion potentials for the Amber ff99SB protein force field. Proteins 78, 1950-1958 (2010).
60. Wang, H., Dommert, F. & Holm, C. Optimizing working parameters of the smooth particle mesh Ewald algorithm in terms of accuracy and efficiency. J Chem Phys 133, 034117 (2010).
61. Hess, B., Bekker, H., Berendsen, H. J. & Fraaije, J. G. LINCS: a linear constraint solver for molecular simulations. Journal of computational chemistry 18, 1463-1472 (1997).
62. Pronk, S. et al. GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics 29, 845-854 (2013).
63. DeLano, W. L. The PyMOL molecular graphics system (2002).
64. Maisuradze, G. G., Liwo, A. & Scheraga, H. A. Principal component analysis for protein folding dynamics. J Mol Biol 385, 312-329 (2009).
65. David, C. C. & Jacobs, D. J. Principal component analysis: a method for determining the essential dynamics of proteins. Methods Mol Biol 1084, 193-226 (2014).
66. Hoang, T. X., Trovato, A., Seno, F., Banavar, J. R. & Maritan, A. Geometry and symmetry presculpt the free-energy landscape of proteins. Proc Natl Acad Sci U S A 101, 7960-7964 (2004).
67. Mocak, J. & Bond, A. Use of MATHEMATICA software for theoretical analysis of linear sweep voltammograms. Journal of Electroanalytical Chemistry 561, 191-202 (2004).
68. Upadhyay, S. K. Dynamics of Gal80p in the Gal80p-Gal3p complex differ significantly from the dynamics in the Gal80p-Gal1p complex: implications for the higher specificity of Gal3p. Mol Biosyst 10, 3120-3129 (2014).
69. Chillemi, G. et al. Thr729 in human topoisomerase I modulates anti-cancer drug resistance by altering protein domain communications as suggested by molecular dynamics simulations. Nucleic Acids Res 36, 5645-5651 (2008).
70. Kumari, R. & Kumar, R. Open Source Drug Discovery, C. & Lynn, A. g-mmpbsa-a GROMACS tool for high-throughput MMPBSA calculations. J Chem Inf Model 54, 1951-1962 (2014).
71. Hou, T., Wang, J., Li, Y. & Wang, W. Assessing the performance of the molecular mechanics/Poisson Boltzmann surface area and molecular mechanics/generalized Born surface area methods. II. The accuracy of ranking poses generated from docking. J Comput Chem 32, 866-877 (2011).
72. Homeyer, N. & Gohlke, H. Free Energy Calculations by the Molecular Mechanics Poisson-Boltzmann Surface Area Method. Mol Inform 31, 114-122 (2012).
73. Miller, B. R. 3rd et al. MMPBSA.py: An Efficient Program for End-State Free Energy Calculations. J Chem Theory Comput 8, 3314-3321 (2012).